trial
as of 2026-07-01PEARL Schizophrenia Maintenance
NCTId NCT01435928
at a glance
Phase 3 · Completed
Enrollment 676 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
676 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-09
Primary completion
2013-08
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
75 total
Springdale, United StatesLittle Rock, United StatesLittle Rock, United StatesCerritos, United StatesDowney, United StatesEscondido, United StatesGarden Grove, United StatesLos Angeles, United StatesNational City, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
676
Phase
PHASE3
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person